Site search
2901 results for '' found
First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein
First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein
/
A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor
A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor
/
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)
/
Comparing speech pathology and amitriptyline to speech pathology and placebo for the management of vocal cord dysfunction: a randomised controlled trial (ACTRN12619000158167)
Comparing speech pathology and amitriptyline to speech pathology and placebo for the management of vocal cord dysfunction: a randomised controlled trial (ACTRN12619000158167)
/
https://app.prompt.org.au/download/253190?code=bf75f8cc-636e-4810-afcc-8ced5fffb360
Life in the Alfred ICU
Most people who pass by The Alfred’s ICU building are unaware of what happens inside – but anyone who has entered its doors as a staff member, a patient or a loved one, will have a compelling story to tell.
/news/the-many-faces-of-the-alfreds-icu
World-first trial takes aim at deadly silicosis
New hope is on the horizon for silicosis sufferers with Melbourne experts set to embark on a world-first trial designed to halt progression of the deadly lung disease.
/news/world-first-trial-takes-aim-at-deadly-silicosis
Alfred_Health_GP_News_-_August_2025.pdf
Vic’s road to transplant
As 54 year old Vic Wiggins waited for a lifesaving heart transplant, he never gave up hope he’d one day be able to join his son on a long bike ride.
/news/vics-road-to-transplant